この論文にアクセスする

この論文をさがす

抄録

[Purpose]: To study the association of ARMS2 A69S genotype with the development of exudative age-related macular degeneration (AMD) in the unaffected fellow eye and to estimate the duration until the development of AMD in the second eye. [Design]: Retrospective cohort study. [Methods]: We retrospectively reviewed 326 patients who had exudative AMD in at least 1 eye, genotyping of ARMS2 A69S, and a minimum follow-up of 2 years. Survival analysis and Cox proportional hazard regression analysis were used to examine the association between candidate factors and the duration until the development of AMD in the second eye. [Results]: One hundred nineteen patients (36.5%) had bilateral exudative AMD at the initial visit. A risk allele of ARMS2 A69S was more frequently seen in patients with bilateral AMD (P = .0270) than in those with unilateral AMD. Of the 207 unilateral AMD patients, 23 (11.1%) had AMD in the fellow eye after a mean duration of 56.3 ± 40.4 months. Fellow-eye involvement was associated with ARMS2 A69S genotype (hazard ratio [HR], 2.673; P = .0013), age (HR, 1.102; P = .0005), and smoking history (HR, 0.680; P = .3663). As HRs indicate, correlation of genotype (2.673) was as high as that of 10-year aging (1.10210 = 2.641). Survival analysis revealed that patients with risk homozygous (TT) genotype had second-eye involvement significantly earlier than those with other genotypes (P = .0028). When the observation duration reached 120 months, second-eye involvement had developed in 50%, 6.6%, and 11.2% of the TT, GT, and GG cohorts, respectively. [Conclusion]: ARMS2 A69S genotype is associated with second-eye involvement of exudative AMD and with the period between first- and second-eye involvements.

収録刊行物

  • American journal of ophthalmology

    American journal of ophthalmology 154(3), 542-548.e1, 2012-09

    Elsevier Inc.

被引用文献:  2件中 1-2件 を表示

各種コード

  • NII論文ID(NAID)
    120004874011
  • NII書誌ID(NCID)
    AA11523017
  • 本文言語コード
    ENG
  • 資料種別
    journal article
  • ISSN
    0002-9394
  • データ提供元
    CJP引用  IR 
ページトップへ